Key result
Animal models with genetically engineered DAG1 have clarified the crucial role of dystroglycan in skeletal muscle and the contribution of single amino acids to muscular dystrophy.
This review summarizes animal models developed to study dystroglycan function and its role in muscular dystrophy through genetic engineering of the DAG1 gene.
Dystroglycan-targeted approaches merit exploration in muscular dystrophy; leaves open clinical translation from these animal models.
In skeletal muscle, dystroglycan (DG) is the central component of the dystrophin-glycoprotein complex (DGC), a multimeric protein complex that ensures a strong mechanical link between the extracellular matrix and the cytoskeleton. Several muscular dystrophies arise from mutations hitting most of the components of the DGC. Mutations within the DG gene (DAG1) have been recently associated with two forms of muscular dystrophy, one displaying a milder and one a more severe phenotype. This review focuses specifically on the animal (murine and others) model systems that have been developed with the aim of directly engineering DAG1 in order to study the DG function in skeletal muscle as well as in other tissues. In the last years, conditional animal models overcoming the embryonic lethality of the DG knock-out in mouse have been generated and helped clarifying the crucial role of DG in skeletal muscle, while an increasing number of studies on knock-in mice are aimed at understanding the contribution of single amino acids to the stability of DG and to the possible development of muscular dystrophy.
No takes yet. Share an insight, caveat, or question.
Sciandra et al. (2015) conducted a review in Muscular Dystrophy. Genetic engineering of DAG1 was evaluated. Animal models with genetically engineered DAG1 have clarified the crucial role of dystroglycan in skeletal muscle and the contribution of single amino acids to muscular dystrophy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: